
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Newron will sponsor the study and be responsible for Xadago (safinamide), development and execution, as well as leading on all related regulatory interactions. Newron and Zambon will evenly share the cost of the study.
Product Name : Xadago
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 12, 2021
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Newron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Riluzole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable
Riluzole Orodispersible Film Replicate Bioavailability
Details : Riluzole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Riluzole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Cross Research S.A.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Voriconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Details : Voriconazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Aspergillosis, Allergic Bronchopulmonary.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Voriconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiolitis Obliterans.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 27, 2019
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cyclosporine is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bronchiolitis Obliterans.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 31, 2019
Lead Product(s) : Cyclosporine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acetylcysteine
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N-Acetylcysteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Retinitis Pigmentosa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2019
Lead Product(s) : Acetylcysteine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable

Safinamide for Levodopa-induced Dyskinesia (PD-LID)
Details : Safinamide Methane Sulfonate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dyskinesia, Drug-Induced.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 17, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2019
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : N-Acetylcysteine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Tract Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2019
Lead Product(s) : Acetylcysteine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Safinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2019
Lead Product(s) : Safinamide Methanesulfonate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
